Cataract surgery and diabetic macular edema progression
Part of Eyes & vision clinical trials.
This trial studies how diabetic macular edema (swelling in the center of the retina) might change after cataract surgery. It may help doctors understand if surgery is safe for people with this condition.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have diabetes and have non-center-involving diabetic macular edema (swelling in the retina that does not affect the central part)
- You have a mild to moderate nuclear cataract (a type of clouding in the lens of your eye)
- You do not have severe diabetic retinopathy or advanced eye damage
- You have not had a traumatic cataract (caused by injury)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether a medication called dapagliflozin, which is usually used for diabetes and heart failure, can help reduce swelling in the retina (diabetic macular edema) and improve vision. It is for people with type 2 diabetes who are already taking insulin and metformin.
This trial tests a new medication, CU06-1004, for people with diabetic macular edema, a condition that causes blurry vision due to fluid buildup in the central part of the retina. The goal is to see if this drug can reduce the swelling and improve vision.
This trial tests a more frequent dosing of an eye injection called pegaptanib (Macugen) to see if it can quickly reduce swelling in the retina caused by diabetes and improve vision. It is for people with diabetic macular edema who have some vision loss.
This Phase 1 trial tests MS-553 to see how it works and how safely it can be given to people with diabetic retinopathy causing central macular swelling (macular edema). You may be considered if your vision and eye scan results match, and if you can follow frequent study visits.
This trial tests a gene therapy called RGX-314 for people with diabetic macular edema that affects the center of the vision. If you have had previous treatment and still have swelling, this study may be an option.
This Phase 1 study tests the safety and early effectiveness of OCU200 eye injections in people with diabetic macular edema (DME) that affects the center of vision. It may help by reducing the eye swelling that blurs vision from diabetes.
Hear when a new Diabetic Macular Edema trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.